Targeting PPAR as a therapy to treat multiple sclerosis

Area of Science:

• Neuroimmunology
• Molecular Biology

Background:

• Multiple sclerosis (MS) is a chronic, disabling neurological disorder with unknown etiology, often considered an autoimmune CNS inflammatory disease.
• Current treatments focus on symptom management, as no definitive cure for MS exists.
• MS poses significant socio-economic challenges, particularly for young adults.

Purpose of the Study:

• To investigate the therapeutic potential and mechanisms of Peroxisome proliferator-activated receptor (PPAR) agonists in multiple sclerosis (MS) treatment.
• To explore how PPAR agonists, known regulators of inflammation, may impact MS pathogenesis.

Main Methods:

• Review of recent scientific literature on PPAR agonists and their effects in MS animal models.
• Analysis of studies demonstrating the anti-inflammatory actions of PPAR agonists.

Main Results:

• PPAR agonists have demonstrated beneficial effects in preclinical models of MS.
• These agonists function by inhibiting key inflammatory signaling pathways implicated in MS.

Conclusions:

• PPAR agonists represent a promising therapeutic strategy for managing MS by targeting inflammatory processes.
• Ongoing human clinical trials are expected to validate the safety and efficacy of PPAR agonists for MS treatment.